What is the market's earnings forecast for Jaguar Health next quarter?

What is the revenue and EPS growth rate for Jaguar Health year over year?

Did Jaguar Health beat or miss consensus estimates last quarter?

What were the key takeaways from Jaguar Health’s earnings call?

What were the key takeaways from Jaguar Health's earnings call?

What factors drove the changes in Jaguar Health's revenue and profit?

What is Jaguar Health's latest dividend and current dividend yield?

What is Jaguar Health's gross profit margin?

- **Revenue Resilience**: Q3 2025 revenue up 4% QoQ, despite Mytesi volume decline, signaling diversification efforts.
- **Clinical Breakthroughs**: Crofelemer reduces parenteral support in ultra-rare MVID (37%) and SBS (12%), with no competitors in MVID space.
- **Cancer Diarrhea Opportunity**: Potential 2026 NDA for metastatic breast cancer, targeting 160,000 U.S. patients with life-saving therapies at risk.
- **Animal Health Expansion**: Canalevia poised for EU approval and U.S. indication expansion, with partnerships in final stages.
- **Financial Efficiency**: Narrowing net loss and EBITDA improvements reflect cost management amid R&D investments.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue of $3.1 million, up 4% from Q2 2025, though down 3.6% year-over-year for Mytesi prescription volume.
- **MVID/SBS Progress**: Crofelemer reduced parenteral support by 37% in MVID patients and 12% in SBS patients, with no approved treatments for MVID. FDA Type C meeting laid groundwork for potential 2026 NDA filing.
- **CTD Expansion**: Supplemental NDA for cancer therapy-related diarrhea in metastatic breast cancer, with randomized withdrawal trial set for 2026. Orphan drug designation filed.
- **Animal Health**: Canalevia for chemotherapy-induced diarrhea in dogs approved in the U.S., with discussions for EU approval and expansion to general diarrhea.

**【CFO Financial Commentary】**
- **Financial Performance**: Loss from operations decreased to $7.3 million (Q3 2025 vs. $7.2 million in 2024). Net loss attributable to common shareholders improved to $9.5 million (from $9.9 million in 2024).
- **Non-GAAP Metrics**: Non-GAAP recurring EBITDA loss of $8.9 million (Q3 2025) vs. $9.2 million in 2024.
- **Revenue Breakdown**: Prescription and non-prescription products, including license revenue, drove Q3 growth.

**【Upcoming Catalysts】**
- **Human Health**: Potential NDA filings for MVID/SBS and CTD by end-2026, with FDA breakthrough designation and EU PRIME designation in process.
- **Animal Health**: Expected partnership closure for Canalevia commercialization in 2026.
- **Funding Strategy**: Pursuing non-dilutive collaborations to support late-stage development.

Jaguar Health, Inc.(JAGX)-20251117-2025 Q3 Earnings call transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

JAGX

JAGX fundamentals

You can ask Aime